{"schema_version":"secwatch.filing_event.v1","accession":"0001759425-24-000017","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.927716+00:00","generated_at":"2026-06-02T12:05:09.612186+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mirum Q1 revenue $69.2M, up 119% YoY; reaffirms FY guidance $310-320M","bullets":["Global product sales net $68.9M, up 137% vs Q1 2023; LIVMARLI net sales $42.8M (+47%).","FDA approved LIVMARLI for PFIC cholestatic pruritus in March 2024.","Volixibat interim analyses (VISTAS/VANTAGE) expected June 2024; CHENODAL NDA for CTX on track H1 2024.","Cash and equivalents $302.8M as of March 31, 2024, up from $286.3M at year-end 2023.","Operating expenses $95.7M (incl. $17.1M non-cash items) vs $58.7M in prior-year quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001759425-24-000017","json":"https://secwatch.observer/filing/0001759425-24-000017.json","markdown":"https://secwatch.observer/filing/0001759425-24-000017.md","text":"https://secwatch.observer/filing/0001759425-24-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000175942524000017/0001759425-24-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000175942524000017/mirm-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:05:09.612186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9f70d48457ac8e279864b65cccfdd8bb149bfc46","claim":"Mirum Pharmaceuticals, Inc. reported the quarter ended March 31, 2024 results: revenue $69.2 million. Guidance reaffirmed.","evidence_excerpt":"such filing. --- EX-99.1 (EX-99.1) --- Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update • First quarter 2024 total revenue of $69.2 million, on track to achieve full-year guidance of $310 to $320 million • FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients achieved in March • Volixibat VISTAS and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000175942524000017/0001759425-24-000017-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$69.2 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}